All News
Unmasking Lupus Pregnancy: Adherence and Drug Monitoring Dilemmas
Risk of poor pregnancy outcomes in lupus patients continues to remain high, especially in the setting of high disease activity. Preliminary data from a lupus pregnancy LEGACY cohort presented at EULAR 2023 raise concern.
Read Article
Key points from #EULAR2023 on how to manage SLE
@RheumNow https://t.co/vJy7Cg7w8N
David Liew drdavidliew ( View Tweet)
#ClinicalPearl This is cool - think of SGLT2 for #lupus #nephritis? presented at #SLE recommendations @RheumNow #EULAR2023 @eular_org https://t.co/8mbNt2n64v
Janet Pope Janetbirdope ( View Tweet)
#SLE #EULAR recommendations What is new - use LESS #glucocorticoids, aim for none or 5 mg/d or less, use #biologics early if needed to prevent damage, #lupus #nephritis consider less pulse dose if using, voclosporin vs Belimumab ? it depends @RheumNow #EULAR2023 https://t.co/Ylnnl3pHOK
Janet Pope Janetbirdope ( View Tweet)
Diagnostic delay in #lupus is really prevalent!
#EULAR2023 @RheumNow
20% with new lupus diagnosis are hospitalized!
20% diagnosis is delayed for more than 3 months! https://t.co/1vCcezBrQS
Bella Mehta bella_mehta ( View Tweet)
Meds in #lupus at #EULAR2023 recs
- HCQ first line therapy. Target dose remains the same. Some discussion on monitoring levels if possible
- MAIN CHANGE - Glucocorticoids to be minimized (only use for bridging). Nephrologists more so in favor of steroid free remission @RheumNow https://t.co/d8WnUOgrwq
Bella Mehta bella_mehta ( View Tweet)
CAR-T cells in refarctory SLE- long term data presented #EULAR2023
Pts did well except some mild cytopenias. Pts remained in remission.
Maybe a good option in the near future for refractory pts!
@RheumNow https://t.co/NWoFBipOiQ
Bella Mehta bella_mehta ( View Tweet)
With the single cell RNA sequencing analysis being my more affordable (relatively) and widely used! Science is moving forward. Highlights in basic science and translational data #EULAR2023 @RheumNow https://t.co/sS7xLeNyLW
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 #LB0005 Can we improve trial design of Bcell depletion in #SLE? Feasibility RCT of RTX in organ specific MSK showed: a)feasible to use ultrasound & clinical as endpoints, b)new tool LAMDA is responsive, c)potential worsening before later improvement with RTX @RheumNow https://t.co/kGDZ6EqLtq
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Promising new therapies in SLE
Dr. Yuz Yusof ( @Yuz6Yusof ) weighs in.
The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians.
https://t.co/0G6EMYp2mb https://t.co/Yc31sR4fRE
Links:
Dr. John Cush RheumNow ( View Tweet)
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. John Cush RheumNow ( View Tweet)
#EULAR2023 #OP0290 Heterogeneity in #SLE is not only disease features but think of ANCESTRY. Data from BILAG-BR registry showed worse outcomes in people of Black and South Asian treated with either Rituximab or Belimumab (adjusted for deprivation index) @RheumNow https://t.co/bcdu9RIFSx
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Predictors of first hospitalizations due to disease activity and infections in #lupus 1341 pts from multicenter latin american cohort. 33% with atleast one hospitalization, and 3/4th due to disease activity.
@rheumnow #EULAR2023 abt#POS0169 https://t.co/vbJU4220is
Bella Mehta bella_mehta ( View Tweet)
Evaluation of diagnostic performance of ACR 1997, SLICC 2012 and EULAR /ACR diagnostic crieteria in childhood onset #SLE - SLICC highest sensitivity early in the disease,
ACR1997 has the highest specificity both at diagnosis ans over time.
@RheumNow #EULAR2023 abst#POS0136
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 #POS1124 My newly diagnosed patients & their carers often expressed heightened anxiety with poor quality web info about #SLE. Thank you @LupusEurope for this wonderful effort 👏. Available in most European languages too @RheumNow https://t.co/cr5Ls117xM
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 #POS1128 Promising new therapy on the block for #lupus nephritis. A single arm Phase 2a study showed Zetomipozomib, selective immunoproteosome-i + MMF showed about 2/3 pts met =>50% reduction in uPCR at WK24. No safety signal including low IgG or infection @RheumNow https://t.co/0A8cCW5GVV
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 #OP0226 DORIS remission in #SLE is a goal but may be slight tricky to achieve. Multicentre cohort study showed attainment of LLDAS protected against subsequent Flare and Damage @RheumNow https://t.co/MIypIDW6aE
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
We know HCQ adherence is poor in both RA and SLE
>50% in this BC 🇨🇦 cohort
All despite being such an important medicine
What’s super interesting are the trajectories of adherence - and we’d like to understand more about what motivates each group
OP0222 #EULAR2023 @RheumNow https://t.co/rbx1l9T36C
David Liew drdavidliew ( View Tweet)
Antimalarial adherence in RA and SLE showed 4 patterns of adherence over time, with 53% drop off in 1 year, with higher adherence with age, SLE and socioeconomic class, Hoque MR, Abst#0222 #EULAR2023 @RheumNow https://t.co/Bld5kWVQxE
Dr. Antoni Chan synovialjoints ( View Tweet)
Fatigue in SLE remains a challenge!
Online digital tool - LEAF - Lupus Expert System for Assessment of Fatigue - assement of fatigue PROMs in 1250pts - 80% reported fatigue, 93% found tool helpful @rheumnow #EULAR2023
Need more tools to assess and manage fatigue!
abst#OP0230
Bella Mehta bella_mehta ( View Tweet)
